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Acinetobacter baumannii is a non-fermenting, aerobic Gram-negative bacillus
that is distributed evenly in the hospital environment,
1 and is an important
opportunistic pathogen which causes nosocomial infections, especially in
intensive care units. The known risk factors for A. baumannii colonization or
infection include prolonged hospitalization, intensive care unit (ICU) admission,
emergency surgical operation, total parenteral nutrition, invasive procedures, or
previous broad-spectrum antibiotic use. A. baumannii causes a variety of
nosocomial infections including septicemia, pneumonia, endocarditis, meningitis,
wound infection and urinary tract infection.
1 Carbapenems are the antibiotics of
choice against multidrug resistant A. baumannii infections. However, the
incidence of carbapenem-resistant A. baumannii is now being increasingly
reported worldwide, thus causing serious therapeutic problems.
2 Imipenem is one
of the most effective carbapenems for the treatment for the infection caused by
multidrug resistant A. baumannii. It causes good porin permeability of the outer
Original Article
DOI 10.3349/ymj.2009.50.6.764
pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 50(6): 764-770, 2009
Outbreaks of Imipenem Resistant Acinetobacter
BaumanniiProducing OXA-23 β-Lactamase 
in a Tertiary Care Hospital in Korea
Hee Young Yang,
1Hee Joo Lee,
1Jin Tae Suh,
1and Kyeong Min Lee
2
1Department of Laboratory Medicine, College of Medicine, Kyung Hee University, Seoul; 
2Division of Antimicrobial Resistance, National Institute of Health, Korea Centers for Disease Control and Prevention, Seoul, Korea. 
Purpose: Since November 2006, imipenem-resistant Acinetobacter baumannii isolates have increased in Kyung
Hee University Hospital in Seoul, Korea. The purpose of this study was to determine the genetic basis and
molecular epidemiology of outbreak isolates. Materials and Methods: Forty-nine non-repetitive isolates of the
734 IRAB strains were investigated in order to determine their characteristics. The modified Hodge and the
ethylenediaminetetraacetic acid (EDTA)-disk synergy test were performed for the screening of carbapenemase and
metallo-β-lactamase production. Multiplex polymerase chain reaction (PCR) assays were performed for the
detection of genes encoding for OXA-23-like, OXA-24-like, OXA-58-like and OXA-51-like carbapenemase.
Pulsed-field gel electrophoresis (PFGE) was performed for strain identification. Results: All isolates showed 100%
resistance to ciprofloxacin and gentamicin, 97.9% resistance to cefepime, piperacillin/tazobactam, aztreonam,
ceftazidime and piperacillin, 93.9% resistance to tobramycin and 57.1% resistance to amikacin. All of the 49
isolates (100%) showed positive results in the modified Hodge test and negative results in the EDTA-disk synergy
test. They all (100%) possessed the encoding gene for an intrinsic OXA-51-like carbapenemase and an acquired
OXA-23-like carbapenemase in the multiplex PCR assay. PFGE patterns revealed that all isolates were clonally
related from A1 to A14. Conclusion: It is concluded that all of the 49 IRAB isolates acquired resistance to
imipenem by producing OXA-23 carbapenemase and they might have originated from a common source.
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INTRODUCTIONmembrane, and has affinity for penicillin-binding proteins,
and stable β-lactamase.
3 However, imipenem-resistant A.
baumannii are being reported increasingly, ranging from
6.3% in 1999 to 13% in 2003 in Korea.
4,5
Since November 2006, cases of imipenem-resistant A.
baumannii have increased in Kyung Hee University Hos-
pital in Seoul, Korea. The purpose of this study is to deter-
mine the genetic basis and molecular epidemiology of
these outbreak isolates.
Microbiologic evaluation
A total of 734 imipenem-resistant A. baumannii isolates
were isolated from November 2006 to July 2007 at Kyung
Hee University hospital in Seoul, Korea. The isolates were
identified by conventional identification techniques and a
MicroScan Walkaway 96 (Dade Behring, West Sacramento,
CA, USA). Forty-nine (49) non-repetitive isolates of the 734
imipenem-resistant A. baumannii strains were investigated
in order to determine their characteristics.
Antimicrobial susceptibility testing
The testing was performed by two methods; One was
minimum inhibitory concentrations (MIC) using a com-
mercially prepared panel (MicroScan Walkaway 96) for
blood specimens, and the other was the disk diffusion
method for other specimens. The results were interpreted
according to the guidelines of the Clinical Laboratory
Standards Institute (CLSI).
6
β β-lactamase assays 
A modified Hodge test was performed to screen carbape-
nemase production. A suspension of Escherichia coli
ATCC 25922, which was adjusted to the turbidity of the
McFarland No. 0.5 tube was inoculated evenly on a Mueller-
Hinton agar plate. Then, an imipenem disk (30 µg, BBL)
was placed at the center of the plate. Test strains were
streaked heavily from the edge of the disk to the periphery
of the plate. The presence of a distorted inhibition zone
after 16 to 18 hours of incubation at 35˚C was interpreted
as a positive modified Hodge test. An ethylenediamine-
tetraacetic acid (EDTA)-disk synergy test was used for the
screening of metallo-β-lactamase production. The test
strains were suspended to the turbidity of the McFarland
No. 0.5 tube and used to swab and inoculate a Mueller-
Hinton agar plate. A 30 µg imipenem disk and a blank
filter paper disk were placed 10 mm apart from edge to
edge on the agar plate. Ten µL of 0.5 M EDTA solution was
applied to the blank disk, which resulted in approximately
a 1.5 mg/disk. After 16 to 18 hours of incubation at 35˚C,
the presence of an enlarged zone of inhibition was inter-
preted as EDTA-synergy test positive.
7
Detection of carbapenem-resistant genes 
A multiplex polymerase chain reaction (PCR) assay was
performed for the detection of the carbapenem-resistant
genes in the A. baumannii isolates according to the method
described by Woodford, et al.
8 These primers were combined
with eight primers which were designed to amplify frag-
ments of genes encoding for OXA-23-like, OXA-24-like,
OXA-58-like and OXA-51-like carbapenemase. The
amplification conditions were: initial denaturation at 94˚C
for 5 minutes, 30 cycles of 94˚C for 25 seconds, 52˚C for
40 seconds, 72˚C for 50 seconds, and a final elongation at
72˚C for 6 minutes (Table 1).
Pulsed-field gel electrophoresis
The sample plugs were digested with 150 µL of ApaI
reaction buffer containing 10 U of the ApaI restriction
enzyme (New England Biolabs, Ipswich, MA, USA).
DNA fragments were separated by electrophoresis in a 1%
SeaKem gold agarose gel, using a 0.5× TBE buffer (45
mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.0) with
CHEF Mapper
® XA (Bio-Rad Laboratories, Hercules, CA,
USA) at 14˚C and 6 V/cm. The electrophoresis was carried
out by using alternating pulses at a 120
O angle, with a 5-20
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MATERIALS AND METHODS
Table 1.Multiplex PCR Primers for the Detection of Genes Encoding OXA Carbapenemase
Primers Primer sequence (5’-3’) Product size (bp)
OXA-51-like
TAATGCTTTGATCGGCCTTG
353
TGGATTGCACTTCATCTTGG
OXA-23-like
GATCGGATTGGAGAACCAGA
501
ATTTCTGACCGCATTTCCAT
OXA-24-like
GGTTAGTTGGCCCCCTTAAA
246
AGTTGAGCGAAAAGGGGATT
OXA-58-like
AAGTATTGGGGCTTGTGCTG
599
CCCCTCTGCGCTCTACATAC
PCR, polymerase chain reaction.Hee Young Yang, et al.
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Table 2.Clinical Characteristics of Patients in Imipenem Resistant Acinetobacter Baumannii Outbreak
No. Isolate
Age /  Hospital 
Specimen
PFGE Days since 
Underlying- disease Diagnosis
gender ward pattern admission
1 06.11.21 76 / F MICU Sputum A7 4 Intracranial hemorrhage Pneumonia, UTI
2 06.11.27 55 / M NICU Sputum A1 43 Intracranial hemorrhage Pneumonia
3 06.12.15 75 / F MICU Wound A2 61 Pancreatitis Pneumonia, UTI
4 07.01.15 68 / M MICU Blood A1 71 Acute myeloid leukemia Pneumonia
5 07.01.19 77 / F SICU Blood A4 11 Duodenal ulcer perforation Pneumonia
6 07.02.05 63 / M General ward Sputum A4 165 Acute renal failure Septicemia
7 07.02.05 77 / M MICU Sputum A1 19 Chronic renal failure Pneumonia
8 07.02.05 71 / M MICU Sputum A4 43 Congestive heart failure Pneumonia
9 07.02.06 68 / M MICU Sputum A1 56 Pulmonary tuberculosis Pneumonia, UTI, Septicemia
10 07.02.06 66 / F MICU Sputum A1 43 End stage renal disorder Pneumonia, Sepsis
11 07.02.07 84 / M MICU Sputum A4 169 Acute cholecystitis  Pneumonia, UTI
12 07.02.08 60 / F SICU Sputum A1 11 Liver abscess Pneumonia
13 07.02.08 48 / M MICU Sputum A4 20 Liver cirrosis, Hepatic encephalitis Pneumonia
14 07.02.09 83 / M MICU Sputum A5 28 Duodenal ulcer bleeding Pneumonia
15 07.02.19 68 / M General ward Sputum A7 17 Bladder tumor
16 07.02.19 58 / M General ward Sputum A4 25 Paralytic ileus Asymptomatic bacteremia
17 07.02.19 71 / M MICU Sputum A1 30 Lung cancer Pneumonia
18 07.02.19 47 / M MICU Sputum A4 20 Pulmonary tuberculosis
19 07.02.19 78 / M MICU Sputum A4 10 Acute renal failure Pneumonia, UTI
20 07.02.24 78 / M MICU Blood A6 15 Acute renal failure Pneumonia, UTI
21 07.03.22 77 / M MICU Blood A5 26 Idiopathic pulmonary fibrosis Pneumonia
22 07.04.02 72 / F MICU Blood A13 13 Idiopathic pulmonary fibrosis Pneumonia
23 07.04.06 42 / F NICU Nose A2 12 Intracranial hemorrhage Pneumonia
24 07.04.09 17 / F SICU Sputum A12 86 End stage renal disorder Pneumonia
25 07.04.09 66 / M MICU Others A7 13 Lymphoma Pneumonia
26 07.04.09 56 / M NICU Sputum A7 11 Cerebral hemorrhage Pneumonia
27 07.04.16 62 / M NICU Blood A14 75 Acute renal failure Pneumonia, Sepsis
28 07.04.20 86 / F NICU Nose A7 10 Subcortical hemorrhage Pneumonia
29 07.04.21 80 / F General ward Sputum A7 17 Cerebral infarction Pneumonia
30 07.04.24 78 / F MICU Sputum A7 29 Congestive heart failure Pneumonia
31 07.04.24 76 / F General ward Wound A1 52 Paraplegia UTI
32 07.04.24 65 / F MICU Sputum A7 25 Cerebral infarction UTI
33 07.04.26 65 / M SICU Nose A7 65 Esophageal cancer Pneumonia
34 07.05.04 71 / M MICU Sputum A1 3 Lung cancer Pneumonia
35 07.05.04 65 / M SICU Sputum A9 74 Esophageal cancer Pneumonia
36 07.05.07 84 / F MICU Urine A7 16 Cerebral infarction Pneumonia
37 07.05.08 84 / F MICU Nose A10 17 Cerebral infarction Pneumonia
38 07.05.08 66 / F MICU Sputum A10 13 Cerebral infarction  Sepsis
39 07.05.09 72 / M NICU Nose A10 58 Hypoxic brain damage Pneumonia
40 07.05.09 77 / M MICU Nose A8 9 Acute cholangitis Septic shock
41 07.05.09 91 / F NICU Nose A7 361 Cerebral infarction Pneumonia, UTI
42 07.05.10 84 / F MICU Sputum A7 20 Congestive heart failure Pneumonia
43 07.05.10 84 / F MICU Wound A11 20 Congestive heart failure Pneumonia
44 07.05.11 52 / M NICU Throat A7 15 Cerebral hemorrhage Pneumonia
45 07.06.20 77 / M MICU Sputum A3 51 Cerebral infarction  Pneumonia, septic shock, DIC
46 07.06.20 58 / M MICU Sputum A1 13 Lung cancer Pneumonia
47 07.06.20 64 / M MICU Sputum A7 19 Idiopathic pulmonary fibrosis Pneumonia, septic shock, DIC
48 07.06.22 72 / M NICU Wound A7 102 Hypoxic brain damage Pneumonia
49 07.07.06 63 / M MICU Blood A7 13 Hemophilia A, acute renal failure Sepsis
MICU, medical intensive care unit; NICU, neurosurgical intensive care unit; SICU, surgical intensive care unit; PFGE, pulsed field gel electrophoresis; UTI, urinary 
tract infection; DIC, Disseminated intravascular coagulation.second pulse time gradient for 19 hours. Cluster analysis
was performed using the unweighted pair group method
with mathematical averaging (UPGMA). DNA relatedness
was calculated using the band-based Dice coefficient with
a tolerance setting of 1.0% band tolerance and 1.0% opti-
mization setting for the entire profile. A similarity of less
than 80% following dendogram analysis was considered to
represent different PFGE types, while a similarity of greater
than 80% was considered to represent PFGE subtypes.
9
Strain identification 
Data collected from the patient’s medical records showed
30 isolates (61.2%) in the medical intensive care unit
(MICU), 9 isolates (18.4%) in the Neurosurgical ICU
(NICU), 5 isolates (10.2%) in the Surgical ICU (SICU),
and 5 isolates (10.2%) in the general wards. Twenty-eight
isolates (57.1%) were obtained from sputum samples. 7
isolates (14.3%) from noses, 7 isolates from blood samples
and 4 isolates (8.2%) from wounds. In addition to those, 3
isolates were from urine, throat and other sites (Table 2).
Antimicrobial susceptibilities 
All isolates showed 100% resistance to ciprofloxacin and
gentamicin, 97.9% resistance to cefepime, piperacillin/
tazobactam, aztreonam, ceftazidime and piperacillin, 93.9%
resistance to tobramycin, and 57.1% resistance to amikacin
(Table 3). 
The modified Hodge and the EDTA-disk synergy test
Among the 49 imipenem-resistant A. baumannii isolates,
all 49 isolates (100%) showed positive results in the modi-
fied Hodge test and negative results in the EDTA-disk
synergy test.
Detection of carbapenem-resistant genes
All 49 isolates (100%) possessed the encoding gene for an
intrinsic OXA-51-like carbapenemase and an acquired
OXA-23-like carbapenemase (Fig. 1).
Pulsed-field gel electrophoresis analysis
All 49 imipenem-resistant A. baumannii isolates showed
an identical band pattern and were classified as pulsotype
A. Pulsotype A isolates were separated into fourteen
subtypes, named subtypes A1 to A14. Sixteen isolates
were subtype A7, three were A10, and two were A2 and
A5. The other subtypes had one isolate each (Fig. 2). 
A. baumannii is an organism which can colonize on the
skin of healthy people. It has the ability to survive for a
long time even in dry condition and the potential for air-
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RESULTS
Fig. 1. Detection of genes encoding OXA carbapenemase by Multiplex PCR.
Lane 1,100 bp Plus DNA Ladder (Bioneer, Daejeon, Korea); Lane 2-12, OXA-23-
like and OXA-51-like. PCR, polymerase chain reaction.
Fig. 2. PFGE profiles of ApaI-digested genomic DNA from isolates of A.
baumannii., PFGE, pulsed-field gel electrophoresis; A. baumannii, Acinetobacter
baumannii.
97.57%
92.95%
88.64%
DISCUSSIONHee Young Yang, et al.
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Table 3. Antimicrobial Susceptibility of Acinetobacter Baumannii Isolates
No PFGE pattern AK CIP GM FEP IPM TZP ATM CAZ PIP TOB
1A 7 RRRRRR RRRR
2A 1 RRRRRR RRRR
3A 2 RRRRRR RRRR
4A 1 RRRRRR RRRR
5A 4 RRRRRR RRRR
6A 4 RRRRRR RRRR
7A 1 RRRRRR RRRR
8A 4 RRRRRR RRRR
9A 1 RRRRRR RRRR
1 0A 1 RRRRRR RRRR
1 1A 4 RRRRRR RRRR
1 2A 1 RRRRRR RRRR
1 3A 4 RRRRRR RRRR
1 4A 5 RRRRRR RRRR
1 5A 7 RRRSRS RRRR
1 6A 4 RRRRRR RRRR
1 7A 1 RRRRRR RRRR
1 8A 4 RRRRRR RRRR
1 9A 4 RRRRRR RRRR
2 0A 6 RRRRRR RRRR
2 1A 5 RRRRRR RRRR
22 A13 IM R R R R R R R R R
2 3A 2 SRRRRR RRRR
2 4 A 1 2RRRRRR RRRR
2 5A 7 SRRRRR RRRR
2 6A 7 SRRRRR RRRR
2 7 A 1 4RRRRRR RRRR
2 8A 7 SRRRRR RRR I M
2 9A 7 SRRRRR RRRR
3 0A 7 SRRRRR RRRR
3 1A 1 SRRRRR RRRS
3 2A 7 SRRRRR RRRR
3 3A 7 SRRRRR RRRR
3 4A 1 RRRRRR RRRR
3 5A 9 RRRRRR RRRR
3 6A 7 RRRRRR RRRR
3 7 A 1 0 SRRRRR RRRR
3 8 A 1 0 SRRRRR RRRR
3 9 A 1 0 SRRRRR RRRR
4 0A 8 SRRRRR RRRR
4 1A 7 SRRRRR RRRR
4 2A 7 SRRRRR RRRR
4 3 A 1 1 SRRRRR RRRR
4 4A 7 SRRRRR RRRR
4 5A 3 SRRRRR RRR I M
4 6A 1 SRRRRR RRRR
4 7A 7 SRRRRR RRRR
48 A7 R R R R R R IM R R R
4 9A 7 RRRRRR RRRR
PFGE, pulsed-field gel electrophoresis; AK, amikacin; CIP, ciprofloxacin; GM, gentamicin; FEP, cefepime; IPM, imipenem; TZP, piperacillin / 
tazobactam; ATM, aztreonam; CAZ, ceftazidime; PIP, piperacillin; TOB, tobramycin; R, resistant; IM, intermediate; S, susceptible.borne transmission.
10,11 Because A. baumannii spreads easily
through contamination of medical equipment used in patient
monitoring or therapy, and from contamination by both
patient and staff during handling of other environmental
sources, these are difficult infections to control.
1,12,13 Gene-
rally, carbapenems (imipenem and meropenem) are the
most active agents for treating nosocomial infections caused
by A. baumannii. However, the emergence of imipenem-
resistant A. baumannii has become a worldwide problem
which is causing serious therapeutic complications.
2
Mechanism of A. baumannii resistance to carbapenems
include the production of carbapenemase, the decreased
outer-membrane permeability caused by the loss or
reduced expression of porins, and the modification of
penicillin-binding proteins. The most common resistance
mechanism involves the acquisition of carbapenem-
hydrolysing β-lactamase which belong to Ambler class B
(metalloenzymes) and predominantly, Ambler class D
(oxacillinase).
14,15 
Ambler class B is a powerful carbapenemase. It is
classified as a metallo β-lactamase (MBL) because it
requires Zn
2+ for the efficient hydrolysis of β-lactams.
Acquired MBLs are divided in to five types; IMP, VIM,
SIM, SPM and GIM. However, only the first three of these
types have been identified in A. baumannii. MBLs are
susceptible to in vitro inhibition by EDTA, a chelater of
divalent cations.
14,15 IMP types have been reported world-
wide, and VIM-2 and SIM-1 have been reported in A. bau-
mannii isolates from South Korea.
14,16,17
The Ambler class D carbapenemases of A. baumannii
are divided into four phylogenetic subgroups; OXA-23-
like (OXA-23, -27 and -49), OXA-24-like (OXA-24/40, -25,
-26 and -72), OXA-58-like (OXA-59 and -96), and OXA-
51-like carbapenemases. The OXA-23 subgroup was first
reported in A. baumannii in Scotland in 1995 and was
originally named ARI-1, but was renamed OXA-23.
19-21
OXA-24 has been reported in Spain. OXA-40 in France,
Spain and Portugal, OXA-23 in Brazil, French Polynesia,
Spain, South Korea and England, and OXA-58 world-
wide.
22-29
The OXA-51-like subgroup may be intrinsic to A.
baumannii, evidenced by its chromosomal location and its
ubiquitous distribution among A. baumannii strains. How-
ever, it is not found in other Acinetobacter species. This
enzyme may be involved in the expression of carbapenem-
resistance under certain circumstances.
30
Treatment for imipenem-resistant A. baumannii infec-
tions is sophisticated. Polymyxins (colinstimethate and
polymyxin B) may be the only remaining therapeutic option.
Colistin was used in the 1960s and 1970s, however was
stopped due to severe adverse effects which included
nephrotoxicity and neurotoxicity, as well as the emergence
of safer alternative antimicrobials.
3
The isolates of imipenem-resistant A. baumannii have
increased abruptly since November 2006. Therefore, our
infection control team was alarmed and started the surveil-
lance program and the outbreak control. During the outbreak
period, environmental contamination with IRAB was found
on patient’s bed, accessories of the mechanical ventilator
and the surrounding environment. And the use of carba-
penem was the significant risk factor for the acquisition of
IRAB during December 2006 in multivariate analysis (p =
0.014). To control the outbreak, the hand washing after
each patient contact, use of gloves and gowns, reinforce-
ment of the environmental disinfection and the adequate
management of the mechanical ventilator were rigorously
enforced. The imipenem-resistant A. baumannii outbreak
sustained for 9-months at our hospital from November
2006 to July 2007. 
In 2005, the OXA-23-producing clones were reported in
a University hospital, Busan, Korea that was the first report
in Asia. Now we are certain that theses clones spread all
over the nation.
In our study, all imipenem-resistant A. baumannii
isolates were positive for carbapenemase production and
negative for metallo-β-lactamase. They all possessed the
encoding gene for an intrinsic OXA-51-like carbapene-
mase and an acquired OXA-23-like carbapenemase. All
isolates analyzed had an identical band pattern, therefore
this outbreak was caused by the spread of a clonally related
epidemic.
The incidence of nosocomial infections due to multidrug
resistant A. baumannii strains is increasing worldwide.
These A. baumannii strains are rapidly adapting to the
hospital environment, so that it is difficult to control the
outbreaks. Early recognition of imipenem resistant A.
baumannii clones is very important to prevent spreading
within the hospital environment. Molecular typing for
multidrug-resistant A. baumannii could be helpful in iden-
tification of a common source or cross contamination. This
is an important step in tracing epidemiology of these strains. 
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